Strategic Growth Capitalize on InspireMD's ongoing TCAR and CGuard Prime program milestones, including 30-day CGUARDIANS II results and upcoming potential FDA approvals, to position strategic partnerships and early-adopter procurement opportunities with vascular centers preparing for new device options.

Clinical Evidence Leverage the robust clinical data backing CGuard Prime and CGUARDIANS studies to engage hospitals and surgeons seeking proven neuroprotection in carotid interventions, highlighting 100% acute device success as a differentiator.

Key Leadership Engage the newly appointed Senior Vice President of Global Sales and Marketing and other leadership-driven initiatives to accelerate adoptions in strategic regions, offering dedicated collaboration on U.S. launch support and channel expansion.

US Commercial Gap Address the current gap where CGuard is not US-approved by presenting near-term regulatory timelines, patient access programs, and non-US installed base to drive cross-border instrument and service partnerships, while preparing US-facing pilots with existing distributors.

Financial Preparedness Target financial and procurement stakeholders by tying demand forecasts to InspireMD’s funding strength and expansive backlog, proposing multi-year supply agreements, volume-based pricing, and joint marketing to accelerate adoption in mid-size cardiovascular centers.